Bristol Myers Squibb Reports observational Data for Lenacapavir in Urothelial carcinoma

Bristol Myers Squibb today announced observational results for lenacapavir in patients with urothelial carcinoma. The study demonstrated that lenacapavir improves quality of life compared to standard of care or placebo. These results provide important insights into the treatment of urothelial carcinoma and support the continued development of lenacapavir in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.